A trial of flunarizine in the treatment of Duchenne muscular dystrophy.
Twenty-seven boys with Duchenne muscular dystrophy (DMD) entered a double-blind controlled trial of treatment with the calcium antagonist flunarizine. They were matched for age and disability. At monthly intervals, muscle power, functional ability, locomotor score, contractures, and forced vital capacity were measured by a team not involved in clinical care. Over a period of 1 year, flunarizine in a dose of up to 0.25 mg/kg/day had no effect on the clinical course of the disease.
D000293:Adolescent; D000818:Animals; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002648:Child; D002936:Cinnarizine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005444:Flunarizine; D006801:Humans; D008297:Male; D009136:Muscular Dystrophies / Q000188:drug therapy* / Q000235:genetics; D051381:Rats; D013577:Syndrome
D002121:Calcium Channel Blockers; D002936:Cinnarizine; D005444:Flunarizine